Covered recipient · General Payments record
ROSEMARY HARRIS
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$1,236.14
- Reported across 67 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $314.89 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $73.33 | 3 |
| Novo Nordisk AS | $43.25 | 2 |
| GlaxoSmithKline, LLC. | $39.08 | 2 |
| Acerta Pharma LLC | $30.89 | 2 |
| SANOFI PASTEUR INC. | $24.54 | 1 |
| Astellas Pharma US Inc | $24.21 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $23.10 | 1 |
| Lundbeck LLC | $21.14 | 1 |
| Janssen Pharmaceuticals, Inc | $18.43 | 1 |
| PFIZER INC. | $16.92 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $19.58 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107295861 | CMS |
| ABBVIE INC. | $32.21 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107295863 | CMS |
| ABBVIE INC. | $21.54 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1107295865 | CMS |
| Astellas Pharma US Inc | $24.21 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139489078 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.52 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104295162 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.37 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105542639 | CMS |
| GlaxoSmithKline, LLC. | $14.03 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116274879 | CMS |
| GlaxoSmithKline, LLC. | $25.05 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116476648 | CMS |
| Janssen Pharmaceuticals, Inc | $18.43 | 01/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078155137 | CMS |
| Lundbeck LLC | $21.14 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146032270 | CMS |
| Novartis Pharmaceuticals Corporation | $23.10 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086958613 | CMS |
| Novo Nordisk Inc | $19.52 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100407308 | CMS |
| Novo Nordisk Inc | $23.73 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100611794 | CMS |
| PFIZER INC. | $16.92 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131035325 | CMS |
| SANOFI PASTEUR INC. | $24.54 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1128741056 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.